Patents by Inventor Stephen L. Yates

Stephen L. Yates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Histamine receptor H3 polynucleotides
    Patent number: 7223839
    Abstract: Novel splice variants of the human H3 histamine receptor are described. The splice variants have deletions of portions of the N-terminal of the wild type H3 receptor. The splice variants are useful in methods for identifying agonists, inverse agonists or antagonists of histamine action at the H3 receptor.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: May 29, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Michael J. Gallagher, Stephen L. Yates
  • Histamine receptor H4 polynucleotides
    Patent number: 7164003
    Abstract: Novel splice variants of the human H4 histamine receptor are described. The splice variants have delections of portions of the N-terminal of the wild type H4 receptor. The splice variants are useful in methods for identifying agonists, inverse agonists or antagonists of histamnie action at the H4 receptor.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: January 16, 2007
    Assignee: Merck & Co. Inc.
    Inventors: Michael J. Gallagher, Stephen L. Yates
  • Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
    Publication number: 20040006120
    Abstract: A method for the use of histamine II3 receptor inverse agonists in the regulation of appetite and treatment of obesity is disclosed. Presently preferred inverse agonists are imidiazole derivatives.
    Type: Application
    Filed: July 14, 2003
    Publication date: January 8, 2004
    Inventors: Stephen L Yates, Clark E Tedford, Kurt R Brunden
  • Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
    Publication number: 20030069295
    Abstract: A method for the use of histamine H3 receptor inverse agonists in the regulation of appetite and treatment of obesity is disclosed. Presently preferred inverse agonists are imidazole derivatives.
    Type: Application
    Filed: August 15, 2001
    Publication date: April 10, 2003
    Applicant: Gliatech, Inc.
    Inventors: Stephen L. Yates, Clark E. Tedford, Kurt R. Brunden
  • 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
    Patent number: 6008240
    Abstract: The present invention provides compounds having H.sub.3 histamine receptor antagonist activity of the general formula: ##STR1## R.sub.2 is a hydrogen or a methyl or ethyl group; R.sub.3 is a hydrogen or a methyl or ethyl group;n is 1, 2, 2, 3, 4, 5, or 6; andR.sub.1 is selected from the group consisting of (a) C.sub.3 to C.sub.8 cycloalkyl; (b) phenyl or substituted phenyl; (c) alkyl; (d) heterocyclic; (e) decahydronapthalene; and (f) octahydroindene;with the provisos thatwhen X is H, A can be --CH.sub.2 CH.sub.2 --,--COCH.sub.2 --,--CONH--,--CON(CH.sub.3), CH.dbd.CH, --c.ident.c--,--CH.sub.2 --NH--, --CH.sub.2 --N(CH.sub.3)--,--CH(OH)CH.sub.2 --,--NH--CH.sub.2 --, --N(CH.sub.3)--CH.sub.2 --,--CH.sub.2 O--,--CH.sub.2 S--, and --NHCOO--;when X is NH.sub.2, NH(CH.sub.3), N(CH.sub.3).sub.2, OH, OCH.sub.3, CH.sub.3, SH, and SCH.sub.3 ; A can be --NHCO--, --N(CH.sub.3)--CO--, --NHCH.sub.2 --, --N(CH.sub.3)--CH.sub.2 --, --CH.dbd.CH--; --COCH.sub.2, --CH.sub.2 CH.sub.2 --,--CH(OH)CH.sub.2, or --C.ident.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: December 28, 1999
    Assignee: Gliatech, Inc.
    Inventors: James G. Phillips, Clark E. Tedford, Amin Mohammed Khan, Stephen L. Yates, Syed M. Ali
  • 2-(4-imidazoyl) cyclopropyl derivatives
    Patent number: 5652258
    Abstract: The present invention provides compounds having H.sub.3 histamine receptor antagonist activity of the general formula: ##STR1## where X is H, A is --CH.sub.2 CH.sub.2 --, --COCH.sub.2 --, --CONH--, --CON(CH.sub.3)--, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 --NH--, --CH.sub.2 --NCH.sub.3 --, --CH(OH)CH.sub.2 --, --NH--CH.sub.2 --, --N(CH.sub.3) --CH.sub.2 --, --NHSO.sub.2 --, --CH.sub.2 O--, --CH.sub.2 S--, CH.sub.2 SO.sub.2 --, or --CH.sub.2 S(O)--;R.sub.2 is a hydrogen or a methyl or ethyl group;R.sub.3 is a hydrogen or a methyl or ethyl group;n is 0, 1, 2, 3, 4, 5, or 6; andR.sub.1 is selected from the group consisting of (a) C.sub.3 to C.sub.8 cycloalkyl; (b) H; (c) phenyl or substituted phenyl; (d) alkyl; (e) heterocyclic; and (f) bicyclic alkyl; andwhenX is NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, OH, OCH.sub.3, NHR.sub.4, OR.sub.4, SH, SR.sub.4, or SO.sub.2 R.sub.4 ; A is --NHCO--, --N(CH.sub.3)--CO--, --NHCH.sub.2 --, --N(CH.sub.3)--CH.sub.2 --, --NHSO.sub.2 --, --CH.dbd.CH--, --CH.dbd.CHF--, --COCH.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 29, 1997
    Assignee: Gliatech, Inc.
    Inventors: James G. Phillips, Clark E. Tedford, Amin Mohammed Khan, Stephen L. Yates